Roux-en-Y Gastric Bypass Improves the Nonalcoholic Steatohepatitis (NASH) of Morbid Obesity

Almeida, Soraya Rodrigues de; Rocha, Paulo Roberto Savassi; Sanches, Marcelo Dias; Leite, Virgínia Hora Rios; Silva, Rogério Augusto Pinto da; Diniz, Marco Túlio Costa; Diniz, Maria de Fátima Haueisen Sander; Rocha, Alexandre Lages Savassi

doi:10.1381/096089206776116462

Cited by 104 publications

(55 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, we had only 11 liver biopsies taken at 1 year follow-up. As expected (44)(45)(46), they consistently showed improved histology (data not shown).…”

Section: Discussionsupporting

confidence: 79%

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Männistö

Simonen

Soininen

et al. 2014

Journal of Lipid Research

View full text Add to dashboard Cite

“…Unfortunately, we had only 11 liver biopsies taken at 1 year follow-up. As expected (44)(45)(46), they consistently showed improved histology (data not shown).…”

Section: Discussionsupporting

confidence: 79%

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Männistö

Simonen

Soininen

et al. 2014

Journal of Lipid Research

View full text Add to dashboard Cite

“…Previous studies in morbidly obese subjects who underwent bariatric surgery for significantly more restrictive dietary control have shown improvement in fibrosis in repeat liver biopsies 2 years after surgery. [17][18][19] It can be speculated that with more prolonged follow up, fibrosis might have improved in these patients because improvement in ballooning degeneration was seen after 9 months of treatment.…”

Section: Discussionmentioning

confidence: 99%

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

Fecht²,

et al. 2008

View full text Add to dashboard Cite

The aim of this study was to determine if orlistat, an inhibitor of fat absorption, combined with caloric restriction in overweight subjects with nonalcoholic steatohepatitis results in weight loss and improved liver histology. Fifty overweight subjects (body mass index ‫؍‬ >27) with biopsy proven nonalcoholic steatohepatitis were randomized to receive a 1,400 Kcal/day diet plus vitamin E (800 IU) daily with or without orlistat (120 mg three times a day) for 36 weeks. Liver biopsies were repeated at week 36. Twenty-three subjects in the orlistat/diet/vitamin E group and 18 in the diet/vitamin E group completed the study. The mean age was 47 ؎ 9.0 (standard deviation) years and mean body mass index was 36.4 ؎ 6.3 kg/m 2 . Four subjects were diabetic. The orlistat group lost a mean of 8.3% body weight compared to 6.0% in the diet plus vitamin E group (not significant). Both groups also had similarly improved serum aminotransferases, hepatic steatosis, necroinflammation, ballooning, and nonalcoholic fatty liver disease activity scores. Stratified according to weight loss instead of treatment group, a loss of >5% body weight (n ‫؍‬ 24) compared to <5% body weight (n ‫؍‬ 17) correlated with improvement in insulin sensitivity (P ‫؍‬ 0.001) and steatosis (P ‫؍‬ 0.015). Comparing subjects who lost >9% of body weight (n ‫؍‬ 16), to those that did not (n ‫؍‬ 25), improved insulin sensitivity (P < 0.001), adiponectin (P ‫؍‬ 0.03), steatosis (P ‫؍‬ 0.005), ballooning (P ‫؍‬ 0.04), inflammation (P ‫؍‬ 0.045), and nonalcoholic fatty liver disease activity score (P ‫؍‬ 0.009) were seen. Increases in adiponectin strongly correlated with improved ballooning and nonalcoholic fatty liver disease activity score (P ‫؍‬ 0.03). Orlistat did not enhance weight loss or improve liver enzymes, measures of insulin resistance, and histopathology. However, subjects who lost >5% of body weight over 9 months improved insulin resistance and steatosis, and those subjects who lost >9% also achieved improved hepatic histologic changes. (HEPATOLOGY 2009;49:80-86.)

show abstract

“…This procedure is performed by making several small incisions and using small instruments and a camera to guide the surgery (laparoscopic approach). This surgery seems to be effective with a low relapse rate (20).…”

Section: Methodsmentioning

confidence: 94%

“…One of the most effective and permanent methods for weight loss is bariatric surgery. Recent studies revealed some improvements in steatosis, inflammation, and liver fibrosis after bariatric surgery, but its efficiency for fatty liver and metabolic disorders was not proven so far (16)(17)(18)(19)(20)(21)(22)(23)(24). In contrast to several studies in this matter, there is a lack of a serum marker, which could be a decent predictive of NAFLD or the severity of NASH disease.…”

Section: Backgroundsmentioning

confidence: 96%

Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery

et al. 2017

View full text Add to dashboard Cite

Background and Objectives: Obesity is one of the most health-threatening phenomena. It is estimated that over 1 billion adults have overweight or obesity. The current study aimed at presenting a detailed account of the findings that attempted to predict the severity of fatty liver disease and its sequelae, including non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, by correlating biopsy results with liver function tests and various metabolic markers of laboratory results in patients with morbid obesity.

show abstract

Roux-en-Y Gastric Bypass Improves the Nonalcoholic Steatohepatitis (NASH) of Morbid Obesity

Abstract: RYGBP improves steatosis, necroinflammatory activity and hepatic fibrosis in patients with morbid obesity and NASH.

Cited by 104 publications

References 29 publications

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery

Contact Info

Product

Resources

About